News Releases

January 5, 2016
Synlogic to Present at the 34th Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., – January 5, 2016 –  Synlogic, a privately-held biopharmaceutical company developing novel medicines based on its proprietary synthetic biology and microbiome platform, today announced that J.C. Gutiérrez-Ramos, Ph.D., Chief Executive Officer of Synlogic will present at a...
September 17, 2015
Synlogic Accelerates Business Growth with Appointment of President, Expansion of Financing, and an Industry Collaboration
Bharatt Chowrira, Ph.D., J.D., appointed as Synlogic’s President bringing industry expertise in corporate development, strategy, intellectual property and financing Two proprietary rare disease programs being advanced into clinical development with accelerated financing An R&D collaboration...
June 11, 2015
Synlogic to Present at Several Upcoming Scientific and Industry Conferences
In vivo efficacy data will be presented for two lead therapeutic programs in development to treat rare genetic metabolic disorders   CAMBRIDGE, Mass. – June 11, 2015  – Synlogic, Inc., a biotechnology company pioneering the development of therapeutic synthetic life, today announced that...
May 21, 2015
Jose-Carlos Gutiérrez-Ramos, Ph.D. Joins Synlogic as Chief Executive Officer
Accomplished drug hunter takes helm of synthetic biology leader as company advances lead therapeutic microbe programs toward clinical testing and executes path to drug discovery platform expansion Company debuts rare disease focused pipeline with two programs directed at genetic metabolism...
October 7, 2014
Synlogic Secures $5 Million Investment in Series A Funding Round
Bill & Melinda Gates Foundation Joins Previously Announced Series A Financing Paul Miller Ph.D. and Alison Silva join Synlogic Leadership Team CAMBRIDGE, Mass. – October 7, 2014  – Synlogic, Inc., a biotechnology company focused on the development of therapeutic microbes, today announced...
July 22, 2014
Synlogic Secures $29.4 Million Series A Financing Led by Atlas Venture and New Enterprise Associates
First-in-class, proprietary synthetic biology platform leveraged for application across multiple diseases CAMBRIDGE, Mass. – July 22, 2014  – Synlogic, Inc., a biotechnology company focused on the development of therapeutic microbes, today announced the company raised $29.4 million in a Series...
Displaying 157 - 162 of 162